Results

• All
• Video
• Audio
• Images

• Most recent
• Filter by category

1–2 of 2 results for UBX1325

• 

  48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2023

• 

  ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD

  Raj K. Maturi, MD

  Annual Meeting Talks

  2023